NDAORALCAPSULE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
(ALK) and inhibits other kinases including MET and ROS1. In vitro, ensartinib inhibited phosphorylation of ALK and its downstream signaling proteins AKT, ERK, and S6, thereby blocking ALK-mediated signaling pathways and inhibiting proliferation in cell lines harboring ALK fusions and mutations. In…
Clinical Trials (1)
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Started May 2017
Loss of Exclusivity
LOE Date
Jun 1, 2037
136 months away
Patent Expiry
Jun 1, 2037
Exclusivity Expiry
Dec 18, 2029
Company
Xcovery
FL - Miami